CN1543345A - 使用匹美莫司进行选择性免疫调节的方法 - Google Patents

使用匹美莫司进行选择性免疫调节的方法 Download PDF

Info

Publication number
CN1543345A
CN1543345A CNA028095200A CN02809520A CN1543345A CN 1543345 A CN1543345 A CN 1543345A CN A028095200 A CNA028095200 A CN A028095200A CN 02809520 A CN02809520 A CN 02809520A CN 1543345 A CN1543345 A CN 1543345A
Authority
CN
China
Prior art keywords
pimecrolimus
treatment
asthma
ibd
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028095200A
Other languages
English (en)
Chinese (zh)
Inventor
S-D・希布
S-D·希布
隙��
A·科迪尔
穆尔
J·克伦
H·D·穆尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1543345A publication Critical patent/CN1543345A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA028095200A 2001-05-09 2002-05-09 使用匹美莫司进行选择性免疫调节的方法 Pending CN1543345A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28984301P 2001-05-09 2001-05-09
US60/289,843 2001-05-09

Publications (1)

Publication Number Publication Date
CN1543345A true CN1543345A (zh) 2004-11-03

Family

ID=23113348

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028095200A Pending CN1543345A (zh) 2001-05-09 2002-05-09 使用匹美莫司进行选择性免疫调节的方法

Country Status (8)

Country Link
US (1) US20030119797A1 (https=)
EP (1) EP1389108A2 (https=)
JP (1) JP2005512946A (https=)
CN (1) CN1543345A (https=)
AU (1) AU2002256507A1 (https=)
BR (1) BR0209474A (https=)
CA (1) CA2442969A1 (https=)
WO (1) WO2002089796A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
JP2006522007A (ja) * 2002-11-15 2006-09-28 ノバルティス アクチエンゲゼルシャフト ドラッグ・デリバリー・システム
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307862D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
ES2367566T3 (es) * 2003-10-06 2011-11-04 Novartis Ag Uso de polimorfismos genéticos que se asocian con la eficacia del tratamiento de una enfermedad inflamatoria.
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
GB0505539D0 (en) * 2005-03-17 2005-04-27 Novartis Ag Organic compounds
KR101278011B1 (ko) * 2005-04-28 2013-06-27 다이닛본 스미토모 세이야꾸 가부시끼가이샤 만성 폐쇄성 폐질환 치료제
NZ581710A (en) * 2007-06-13 2012-02-24 Jay Pravda Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
WO2014074995A1 (en) 2012-11-09 2014-05-15 Scidose, Llc Enema composition for treatment of ulcerative colitis having long term stability
GB201319792D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
JP6716582B2 (ja) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ シクロスポリンを含む組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9318144D0 (en) * 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
ME00189B (me) * 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
WO2001026605A2 (en) * 1999-10-11 2001-04-19 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BR0209474A (pt) 2006-02-07
CA2442969A1 (en) 2002-11-14
EP1389108A2 (en) 2004-02-18
WO2002089796A2 (en) 2002-11-14
JP2005512946A (ja) 2005-05-12
US20030119797A1 (en) 2003-06-26
WO2002089796A3 (en) 2003-03-13
AU2002256507A1 (en) 2002-11-18

Similar Documents

Publication Publication Date Title
CN1543345A (zh) 使用匹美莫司进行选择性免疫调节的方法
Ranganathan et al. Regulation of acute graft-versus-host disease by microRNA-155
Beute et al. A pathophysiological role of PDE3 in allergic airway inflammation
CN1490048A (zh) 提高药剂口服生物可利用率的方法、组合物及试剂盒
CN1309568A (zh) 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法
Zhou et al. Novel genetic association of Wegener's granulomatosis with the interleukin 10 gene.
Matsushita et al. Regnase-1 degradation is crucial for IL-33–and IL-25–mediated ILC2 activation
CN1187084C (zh) α1β1整合蛋白受体抑制剂和TGF－β1抑制剂制备用于治疗肾病的药物组合物的用途
Khaledi et al. COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection
CN1299276A (zh) 依赖于cyp2a酶的治疗和诊断方法
CN1627939A (zh) 二环cb2大麻碱受体配体
US20230270826A1 (en) Antiviral use of liraglutide and gefitinib
CN1927389A (zh) 含有人干扰素的药物组合物在制备预防或/和治疗呼吸道病毒感染疾病药物方面的应用
CN1929855A (zh) 诱导或调节免疫反应的方法
CN1660118A (zh) 含有非那雄胺与环糊精或其衍生物的药物组合物
CN1927388A (zh) 含有人干扰素的药物组合物
CN1816353A (zh) 用于预防或治疗Th1型免疫疾病的药物组合物
CN101049293A (zh) 乙酰半胱氨酸或其药用盐和细辛脑的药物组合物
EP4395778A1 (en) Treatment of lower respiratory tract infection with tradipitant
CN1749415A (zh) 硝酸甘油治疗急性心绞痛疗效检测方法和试剂盒
CN1160119C (zh) Tob基因在哺乳动物中枢神经系统的功能及其应用
Lopez Aspiroz et al. Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy
CN101048160A (zh) 嘌呤和嘧啶cdk抑制剂及其用于治疗自身免疫性疾病
CN1136851C (zh) 一种治疗支气管哮喘和喘息性慢性支气管炎的药物及其制造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned